News
12d
GlobalData on MSNIndia vehicle market under pressure in May – GlobalDataIndia’s Light Vehicle (LV) wholesale figures experienced a 1% month-on-month (MoM) decrease, totaling 399k units, although ...
In an update on the global apparel sector, GlobalData forecasted Adidas will “remain one of the biggest winners within the ...
11d
Just Auto on MSNRegistration is now open for GlobalData’s Global Automotive Outlook Conference 2025GlobalData are delighted to open registration for the Global Automotive Outlook Conference, taking place on October 21, 2025 in Detroit, Michigan.
The HS market across the 7MM is forecast to grow from $1.84bn in 2024 to $7.83bn in 2034, according to GlobalData.
The 2024 approvals included significant milestones in the biosimilar sector, with the FDA granting approval for the first biosimilar of Stelara, Wezlana and the first denosumab biosimilars, Wyost and ...
9d
Just Auto on MSNASEAN 2025 sales outlook revised upwards – GlobalDataThe ASEAN LV market increased by 1% YoY in May, marking the fourth consecutive month of growth, according to figures released by GlobalData.
2d
GlobalData on MSNStryker raises 2025 outlook amid 17.3% medical surgery and neurotechnology unit riseStryker’s financials revealed total sales of $3.7bn in its medical surgery and neurotechnology business unit, up 17.3% on Q2 ...
Global deal activity witnessed a 1.7 per cent year-on-year decline during the first half (H1) of 2025, reflecting a mixed global sentiment amid ongoing economic uncertainties, according to GlobalData.
South Korea’s biopharmaceutical sector has seen a surge in innovator drug licensing agreements, reaching a total deal value of $7.86bn in 2025 year-to-date (YTD), at a 113% increase from 2024, ...
5d
GlobalData on MSNDavis Polk & Wardwell leads consumer M&A law-firm rankings – dataDavis Polk & Wardwell ranked highest by deal value, while Kirkland & Ellis worked on the most transactions by volume.
2d
Clinical Trials Arena on MSNAnavex’s blarcasemine nets win in Phase IIb/III Alzheimer’s extension studyAnavex's blarcasemine met its primary endpoints, improving cognition and function over a four year period in early-stage Alzheimer’s patients.
This is because many people now prefer digital payments over cash. India saw a solid jump in credit card spending in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results